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SUMMARY
Aim: Telemonitoring (TM) is a safe and efficient monitoring system for internal
cardioverter defibrillator device (ICD) recipients. TM has been used to track info on
the clinical status of heart failure patients treated by ICD and/or cardiac resynchro-
nisation therapy defibrillator (CRT-D). The aim of this study was to investigate the
impact of TM on clinical outcomes in a population of CRT-D patients with heart
failure. Methods: In a multicentre, randomised study, patients with chronic heart
failure, New York Heart Association (NYHA) functional class II or III, left bundle
branch block, severe left ventricle ejection fraction reduction (LVEF < 35%) have
been identified and screened. Results: One hundred and ninety-one patients have
been randomised to receive either a CRT-D with TM or a CRT-D with traditional
ambulatory monitoring (control group) and completed the 12-month study follow-
up. Primary endpoints were all cause death, cardiac death and hospital admission
for heart failure. Secondary endpoints were atrial fibrillation, sustained episodes,
non-sustained and self terminated ventricular tachyarrhythmia, sustained ventricular
tachycardia, and ventricular fibrillation, ICD shocks and percentage of CRT-D
responder patients. Univariate analysis identified the following factors predicting
hospitalisation: TM, age, chronic kidney disease, hypercholesterolaemia, LVEF and
NYHA class. At multivariate analysis, TM was the only factor predicting heart fail-
ure hospitalisation (hazard ratio 0.6, 0.42–0.79, 95% CI, p = 0.002), without
affecting overall mortality and cardiac deaths events. Conclusions: Taken
together, our data indicate the importance of TM in predicting heart failure hospi-
talisation in patients treated with CRT-D.
What’s known
Telemonitoring is an efficient monitoring system for
internal cardioverter defibrillator device (ICD)
recipients. It has been used to track info on the
clinical status of heart failure patients treated by ICD
and/or cardiac resynchronisation therapy.
What’s new
This study demonstrates that telemonitoring is an
independent prognostic factor predicting heart failure
hospitalisation in patients treated with cardiac
resynchronisation therapy defibrillator (CRT-D).
Introduction
Since its introduction in the clinical scenario, tele-
monitoring (TM) has rapidly become a diffused sys-
tem to monitor patient’s clinical course and device
function (1–6). Large clinical trials have studied the
TM impact on clinical or device-related events, med-
ical care and resource consumption and follow-up
visits costs (1,7–12). Previous trials have investigated
the TM impact in a population of heart failure
patients treated by ICD, and/or cardiac resynchroni-
sation therapy defibrillator (CRT-D). In heart failure
patients, CRT-D is the choice treatment to improve
symptoms, quality of life, NYHA class and clinical
outcomes, and to prevent heart failure events and
progression (13–15). CRT-D induces a reverse car-
diac remodelling in a percentage of 65% of treated
patients, the so-called ‘CRT-D responders’
(13,16,17). On the other hand, CRT-D non-respon-
ders display poor outcomes, mainly related to a pro-
gressive ventricular dysfunction with an increased
risk of worse clinical outcomes (16,17).
In this scenario, TM, which has just been success-
fully utilised in heart failure patients treated by ICD
and/or CRT-D, may represent a helpful tool to
improve clinical outcomes and CRT-D response. To
our knowledge there are no clinical studies focused
on TM impact in a homogenous population of heart
failure patients (chronic heart failure patients with
left bundle branch block, and left ventricle ejection
fraction reduction (LVEF) < 35%, in NYHA class
II/III) treated by CRT-D. Herein, we have investi-
gated in a randomised, multicentre, prospective
study conducted on a population of heart failure
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patients treated by CRT-D, the impact of CRT on
primary and secondary clinical study endpoints.
Methods
In a randomised, multicentre study conducted in dif-
ferent Italian centres (Catholic University of Sacred
Heart, Campobasso; ‘John Paul II’ Research and Care
Foundation, Campobasso; Second University of
Naples, Naples) between September 2010 and
September 2014 (follow-up has been closed in June
2015), we have enrolled patients with standard indi-
cations (18) for a CRT-D implant, enabled with
[Biotronik (Berlin, Germany) CRT-D models, Lumax
640HF, Iforia 3HF, Iforia 5HF] or without TM
technology [Inogen CRT-D, Incepta CRT-D; Boston
Scientific (Marlborough, MA, USA), Unify Assura
CRT-D; St Jude Medical (St. Paul, MN, USA),
Brava CRT-D; Medtronic (Minneapolis, MN, USA)].
Informed consent was obtained from all participants
included in the study. All procedures were in accor-
dance with the ethical standards of the institutional
and/or national research committee and with the
Helsinki declaration. Enrolled patients had chronic
heart failure lasting for at least 3 months, New York
Heart Association (NYHA) functional class II or III,
left bundle branch block, severe left ventricle ejection
fraction reduction (LVEF < 35%) and an indication
for CRT-D treatment according to the American
College of Cardiology/American Heart Association
guidelines (18). Exclusion criteria were as follows:
age < 18 or > 75 years, ejection fraction > 35%, pre-
vious internal ICD, CRT-D and/or pacemaker
implant, prior cardiac surgery, absence of informed
written consent and any condition that would make
survival for 1 year unlikely. All patients were
informed of the nature of the study and provided
written consent. Screened patients to receive a CRT-
D were defined according to the American College of
Cardiology/American Heart Association guidelines
for the management of patients with heart failure
refractory to a maximal medical therapy (18). After
screening phase, 196 patients have been enrolled in
the study (these patients met criteria reported
above). This population of patients receiving CRT-D
has been randomly divided in TM group and tradi-
tional monitoring (control) group. Baseline parame-
ters have been determined before interventions and
the follow-up has been concluded 12 months after
CRT-D implant. Responders to CRT-D treatment
have been defined as previously described (16).
Interventions
All patients identified to be treated with CRT-D
(heart failure, NYHA class 2–3, LVEF < 35% and left
bundle branch block) were randomly assigned (1 : 1)
to receive TM (TM group) in addition to standard
care (traditional ambulatory clinical and instrumental
assessment), or to standard care without TM (con-
trol group) for 12 months. The random allocation
sequence with variable and randomised block size
(sizes four) was computer-generated and concealed
from the sites. A small portable patient device
receives the data and relays them automatically over
mobile phone links to the Home Monitoring Service
Center. Data were processed automatically and
posted on a server. In the TM group, transmitted
data were reviewed by independent investigators
according to their clinical routine. In parallel, trans-
mitted data were reviewed by a central monitoring
unit composed of trained study nurses and support-
ing physicians, located at the Giovanni Paolo II
Research and Care Foundation, Campobasso (Italy).
The role of this unit was to ensure the awareness of
investigational sites to predefined medical events
including ventricular and atrial tachyarrhythmia epi-
sodes, low percentage of biventricular pacing,
increase in the frequency of ventricular extrasystoles,
decreased patient activity and abnormal intracardiac
electrogram, as described in previous reports (19).
On working days, the central monitoring unit redun-
dantly forwarded these events and standard technical
safety notifications issued by the TM system to inves-
tigational sites. The investigational site had to con-
firm receipt of the reports within 48 h. A clinical
response to TM observations was done at the discre-
tion of investigators. When contacting patients on
the basis of TM data, the investigators did a standard
(prespecified in the protocol) telephone interview to
establish whether the patient’s overall condition or
dyspnoea had worsened, whether the patient was reg-
ularly taking prescribed drugs, and whether the
patient’s weight had increased by more than 2 kg
over the preceding 3 days, followed in any case by a
clinical examination. The investigators reported the
additional clinical follow-up and whether a visit to
the family doctor was recommended. In the control
group, no study participant had access to TM data,
but followed regularly in outpatient clinic ambula-
tory follow-up visits. All patients were treated
according to international guidelines (18).
Surgical procedure
The left ventricle lead was inserted transvenously via
the subclavian route. A coronary sinus venogram was
obtained using a balloon catheter, and the left ventri-
cle pacing lead was inserted through the coronary
sinus with the help of an 8-F or 9-F guiding catheter
and positioned as far as possible in the venous sys-
tem, preferably in the lateral or posterolateral vein.
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The atrial and right ventricular leads were placed in
the right atrial appendage and the right ventricular
apex, respectively. All leads were connected to a
dual-chamber biventricular implantable cardiac
device, with defibrillator function (CRT-D). The atri-
oventricular interval was optimised by Ritter’s
method with transthoracic echocardiography, as pre-
viously described (16).
Patients monitoring
Patients were scheduled for in office follow-up visits
10 days after clinical discharge and after 1, 3, 6 and
12 months by the treating physician (TM and con-
trol group), and every patient was under continuous,
automatic remote monitoring during the entire study
(TM group). The frequency of TM data analysis and
the response to TM alerts was left to the investiga-
tor’s discretion.
The study has been conducted in accordance with
the Declaration of Helsinki. The protocol has been
approved by the Ethics Committees of participating
Institutions. All the patients gave their written
informed consent to participate in the trial.
Data collection and use
All data have been collected at admission visits, fol-
low-up visits and clinical database and during TM
(TM group) and clinical examination (control and
TM group) follow-up. Clinical evaluation included
physical examination, vital signs, review of adverse
events, fasting venous blood withdrawal (at least 12 h
from last meal) have been performed for glycaemia
and lipid profile at every visit. Follow-up visits have
been scheduled 10 days after hospital discharge and
at 1, 3, 6 and 12 months by the treating physician
(the 12th month visit was conducted at the end of
follow-up). At each clinical follow-up, NYHA classifi-
cation was re-assessed and patients graded their over-
all condition as unchanged or slightly, moderately, or
markedly worsened, or improved since randomisation
by global self-assessment. All patients have been
instructed to regularly assess body weight, occurrence
of dyspnoea and any clinical symptom. At each visit,
patients have been asked whether medical events or
symptoms suggestive of cardiac arrhythmias occurred;
moreover, both ECG and ECG Holter-monitoring




The primary endpoints were all cause death, cardiac
death and hospital admission for heart failure (hos-
pitalisation for objective worsening evidence of
change in clinical status, NYHA functional class
changing, patient’s symptoms and quality of life, or
moderately to markedly worse self-reported overall
condition compared with at randomisation). Heart
failure worsening has been also reported as
unplanned overnight admission to hospital, worse
NYHA functional class, or had moderately to mark-
edly worse self-reported overall condition compared
with at randomisation, as described in previous stud-
ies (7,8,20).
Secondary endpoints
Atrial fibrillation (AF) sustained episodes, non-sus-
tained and self terminated ventricular tachyarrhyth-
mia (VTt), sustained VT and ventricular fibrillation
(VF), ICD shocks, percentage of CRT-D responder
patients. The determination of endpoints was adjudi-
cated by an independent clinical committee, accord-
ing to criteria prespecified in the protocol.
Statistical analyses
Continuous data, non-normally distributed, has been
compared with the Mann–Whitney–Wilcoxon rank
sum test. We compared categorical data, including
the primary endpoint with the exact Pearson’s v2
test. Cox regression models were used to calculate
hazard ratios. We considered a two-sided p value of
less than 0.05 as statistically significant. Sample size
was calculated using a power of 80% and confidence
of 95%. The analysis was performed by using SPSS
version 21 (Chicago, IL, USA).
Results
We included in the study 196 eligible patients; 191
received a CRT – subdivided in TM treatment and
traditional CRT-D ambulatory monitoring
(Figure 1); 183 patients terminated the study follow-
up (94 patients in control group, no TM, and 89 in
TM group).
Mean population age was 72.2  7.2. The clinical
characteristics at enrolment were similar and bal-
anced between two groups, as shown in detail in
Table 1. The study population was represented by
chronic heart failure patients, in maximal pharmaco-
logical treatment, receiving CRT-D. No significant
difference was observed when comparing pharmaco-
logical treatment between the two groups (Table 2).
At 1-year follow-up primary and secondary study
endpoints have been examined, comparing TM to
control group (Table 3). We evaluated all different
parameters revealed by TM or by traditional visits,
to differentiate CRT-D responders from non-respon-
ders and to study the primary and the secondary
study endpoints. The patients have been then divided
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in CRT-D responders and CRT-D non-responders,
as indicated by clinical characteristics and response
during follow-up to the CRT-D using criteria previ-
ously described (16). At 1-year follow-up 26 patients
were in persistent AF (7 patients in TM group vs. 19
patients in control group, p = 0.048). There was a
significant difference in hospitalisation events (15.7
vs. 28.7, p = 0.02) comparing TM patients to control
group. There was no significant difference when con-
sidering all cause mortality (7.9 vs. 8.5, p = 0.54) or
cardiac death events (3.4 vs. 5.3, p = 0.39), compar-










Figure 1 Schematic flowchart of the study. Two hundred and sixty patients have been screened because they presented
chronic heart failure in New York Heart Association (NYHA) class 2,3, left bundle branch block, left ventricle ejection
fraction (LVEF) < 35%. After this screening phase, 196 patients have been enrolled in the study (these patients met criteria
reported in Methods). Of these patients four have refused to participate in the study and one has refused to be treated by
cardiac resynchronisation therapy (CRT). After this phase, 191 patients have received a CRT, randomly divided to receive
telemonitoring (TM) and traditional monitoring. 183 patients completed the follow-up, 89 in TM group and 94 in control
group (four patients lost at follow-up in no TM group, two discontinued the study in TM group, two patients referred to
other centres for follow-up visits in control group)
Table 1 Baseline parameters of the study population
Total TM non-TM p
Number of patients 183 89 94
Age 72.2  7.2 71.8  8.5 72.6  5.7 0.43
Male gender, n (%) 139 (75.9) 64 (71.9) 75 (79.8) 0.23
Hypertension, n (%) 109 (59.5) 52 (58.4) 57 (60.6) 0.46
Hypercholesterolaemia, n (%) 106 (57.9) 61 (68.5) 45 (47.9) 0.07
Diabetes, n (%) 110 (60.1) 53 (59.6) 57 (60.6) 0.51
Glucose (mg/dl) 136.4  44.8 141.1  48 132.6  41 0.17
Creatinine 1.23  0.48 1.23  0.48 1.22  0.36 0.46
NYHA (II/III) 83/100 37/52 46/48 0.19
Data are expressed as mean  standard deviation. HF, heart failure; NYHA, New York Heart Association; TM, telemonitoring.
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significant differences when examining responder
percentage, stroke events and number of sustained
VT/VF episodes or ICD shocks events. Notably, at 1-
year follow-up seven patients in TM group vs. 17
patients in control group reported ventricular non-
sustained tachiarrhytmias events (VTt) (p = 0.04).
When considering secondary endpoints, we did not
observe a significant difference in ICD shock events
(event numbers 10 vs. 16, p = 0.208), CRT-D
responder patients percentage [n = 60 (67.4%) vs. 59
(62.8%), p = 0.31], stroke events (n = 3 vs. 4,
p = 0.549) and VT/VF events (n = 18 vs. 23,
p = 0.35) comparing TM to non-TM patients. A sig-
nificant difference has been found when examining
sustained AF episodes (events 7 vs. 19, p = 0.048)
and non-sustained VT episodes (VTt episodes 7 vs.
17, p value 0.04), comparing TM to non-TM
patients.
Then, we evaluated the relative benefits of TM in
CRT-D responders and non-responders by univariate
analysis of factors predicting heart failure hospitalisa-
tion (Table 4). Strikingly, at multivariate analysis of
factors predicting heart failure hospitalisation
(Table 5), TM is the only factor predicting heart fail-
ure hospitalisation [hazard ratio (HR) 0.6, 0.42–0.79,
95% CI, p value 0.002].
Discussion
To our knowledge, this is the first study reporting
TM as a powerful diagnostic tool that can indepen-
dently predict heart failure hospitalisation in patients
Table 2 Pharmacological treatment of the study population
Drugs Total TM non-TM p
Ivabradin 51 (27.9) 27 (30.3) 24 (25.5) 0.28
Carvedilol 71 (38.8) 32 (36.0) 39 (41.5) 0.27
Bisoprolol 102 (55.7) 54 (52.9) 48 (47.1) 0.057
Furosemide 162 (88.50 82 (92.1) 80 (85.1) 0.10
Ace Inhibitors 73 (39.9) 32 (36.0) 41 (43.6) 0.18
Sartans 73 (39.9) 39 (43.8) 34 (36.2) 0.18
Digitalis 51 (27.9) 26 (29.2) 25 (26.6) 0.41
Statins 101 (55.2) 58 (57.4) 43 (42.57) 0.05
Fibrates 22 (12.0) 14 (15.7) 8 (8.5) 0.10
Oral hypocglycaemic drugs 61 (33.3) 34 (38.2) 27 (28.7) 0.11
Insulin 51 (27.9) 30 (31.9) 21 (23.6) 0.13
Amiodarone 37 (20.9) 22 (24.2) 15 (17.4) 0.18
Data are expressed as mean  standard deviation. TM, telemonitoring.
Table 3 Relevant clinical events in telemonitoring
(TM) and non-telemonitoring (non-TM) groups
TM non-TM p
AF 7 19 0.048*
All cause mortality 7 (7.9) 8 (8.5) 0.54
Cardiac death 3 (3.4) 5 (5.3) 0.39
Heart failure Hospitalisation 14 (15.7) 27 (28.7) 0.02*
ICD shocks 10 16 0.208
Responders 60 (67.4) 59 (62.8) 0.31
Stroke 3 4 0.549
VTt 7 17 0.04*
VT/VF 6 11 0.35
Data are expressed as mean  standard deviation. AF, atrial
fibrillation; VTt, total ventricular tachycardia events; VT/VF,
sustained ventricular tachycardia and ventricular fibrillation
episodes; ICD, internal cardioverter defibrillator. *, p < 0.05.
Table 4 Univariate analysis of factors predicting
hospitalisation
HR p
Age (year) 1.11 0.007*
Chronic kidney disease (+ vs -) 1.24 0.011*
Diabetes (+ vs -) 1.39 0.312
Hypercholesterolaemia (+ vs -) 0.76 0.014*
Hypertension (+ vs -) 1.21 0.106
LV ejection fraction (%) 0.96 0.048*
Male vs female 1.11 0.113
NYHA class (class) 0.79 0.016*
TM vs non-TM 0.59 0.002*
HR was calculated via Coz regression models (fixed covariates:
baseline predictors). Data are expressed as mean  standard
deviation. NYHA, New York Heart Association; LV, left
ventricle; TM, telemonitoring. HR, hazard ratio. *, p < 0.05.
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treated with CRT-D. In the MADIT-CRT trial, ran-
domisation to CRT-D was associated with a signifi-
cant reduction in heart failure or death among
patients treated with CRT-D as compared with
patients treated with ICD (13). CRT-D has been also
shown to improve symptoms, quality of life and
NYHA class in responders (13,16,18). Notably, we
did not observe a significant difference in all cause
mortality comparing TM patients to control group,
in contrast with the IN-TIME study, where a lower
mortality in the TM group than in the control group
had been reported. Such a finding may be related to
the study population characteristics. A possible
explanation is that in the IN-TIME study there was a
mixed population including patients treated by ICD
and/or CRT-D: specifically, CRT-D recipients were
58.7% and there were different percentages of CRT-
D responses between TM and non-TM groups (8).
We studied a homogenous population (heart failure
patients, NYHA class 2-3, LVEF < 35% and left bun-
dle branch block) of CRT-D recipients with overall
similar clinical characteristics. Heart failure disease
progression and ventricular dyssynchrony might dif-
ferently affect the prognosis as compared with overall
population and ICD recipients without left ventricle
dyssynchrony. These data have been confirmed by
major trials, including the Mode Selection Trial
(MOST) and the Dual Chamber and VVI Implanta-
ble Defibrillator (DAVID) Trial (21,22). These stud-
ies have determined that right ventricular pacing is
detrimental in terms of heart failure symptoms, and
the current practice is to avoid unnecessary ventricu-
lar pacing in ICD recipients (21,22). Disease progres-
sion, comorbidities and loss of response to CRT-D
may all affect prognosis (21–25), and such parame-
ters may be not influenced by TM. In our study
population, having similar percentages of CRT-D
response (TM vs. non-TM), we found comparable
mortality events rates. Moreover, we did not observe
a significant difference in cardiac death (3.4% vs.
5.3%, p: 0.39) comparing TM to non-TM patients.
Thus, from our analysis, TM does not seem to affect
cardiac mortality in heart failure patients treated by
CRT-D.
Heart failure patients treated with CRT-D (and par-
ticularly CRT-D non-responders) may have a worse
outcome that is more related to disease progression
and ventricular arrhythmias than to the monitoring
technique used. These data are confirmed in large clin-
ical trials as the COMPANION trial, where CRT-D
recipients have a 1-year survival of ~88% (25), and the
MADIT-CRT trial, reporting 1-year survival at 80%
(13). We can speculate that heart failure disease pro-
gression is related to numerous different factors that
may not be influenced by TM. In fact, one relevant
aspect of cardiac death in CRT-D recipients may be
related to VT and/or VF episodes (26). In this sense,
disease progression, occurrence of VT/VF episodes
and ICD shock therapy are not attributable to the
monitoring system utilised, but more to patient risk
factors, clinical characteristics and disease stage. Since
in our study we did not detect significant differences
when considering VT/FV and shock episodes, we
expect to have similar cardiac deaths rates comparing
the two groups. Again in contrast with our current
results, in the IN-TIME study (19), with a 1-year car-
diovascular mortality of ~2.7% in the TM group vs.
6.8% in the control group (log-rank p = 0.012; HR
0.37, 95% CI 0.16–0.83), the Authors concluded that
TM may reduce the percentage of cardiovascular mor-
tality as compared with non-TM patients, treated by
ICD/CRT-D (19). This discrepancy might be because
of the differences in CRT-D non-responders percent-
age between TM and non-TM groups, which may
impact heart failure progression (26). In our popula-
tion we have similar CRT-D response percentages
comparing TM vs. non-TM, and TM does not amelio-
rate the CRT-D response percentage.
A significant difference between TM and non-TM
patients (15.7% vs. 28.7%) has been observed when
examining the hospital admission for heart failure
disease progression (objective worsening evidence of
change in clinical status, NYHA functional class
changing, patient’s symptoms and quality of life, or
moderately to markedly worse self-reported overall
condition) (16). Thus, TM does not reduce overall
cause mortality and cardiac death, in CRT-D recipi-
ents but may change the clinical course of disease
progression. Continuous monitoring and data collec-
tion, interpretation and alarm settings may help the
clinicians in immediate therapy management and
Table 5 Multivariate analysis of factors predicting
hospitalisation
HR 95% CI p
TM vs non-TM 0.60 0.42–0.79 0.002*
Age (year) 1.16 0.81–1.13 0.052
Hypercholesterolaemia (+ vs ) 0.78 0.57–1.04 0.258
Chronic kidney disease (+ vs ) 1.13 0.85–1.37 0.066
NYHA class (class) 0.74 0.49–1.12 0.058
LV ejection fraction (%) 0.97 0.89–0.98 0.083
After testing for collinearity, variables with p < 0.10 on
univariate analysis were included in the multivariate analysis.
Data are expressed as mean  standard deviation. NYHA,
New York Heart Association; LV, left ventricle; TM,
telemonitoring; HR, hazard ratio. CI, confidence interval.
*, p < 0.05.
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adjustments to have the better CRT-D response. We
could consider to use TM to achieve a better clinical
control of CRT-D recipients exploiting common
monitoring mechanisms, including low percentage of
biventricular pacing, early detection of the onset or
progression of arrhythmias, number of device inter-
ventions, early recognition of leads and device dys-
function. Continuous monitoring may be reflected in
a better patient therapeutic management and lower
hospital admission, as compared with periodic out-
patient follow-up.
We did not detect significant differences when
examining stroke events, number of sustained VT/VF
episodes or ICD shocks events. A significant differ-
ence comparing TM to non-TM patients has been
found when examining sustained AF and non-sus-
tained VT episodes. This effect may be in part attri-
butable to a higher prevalence of immediate anti
arrhythmic treatment to restore sinus rhythm in TM
patients as compared with non-TM (27).
In our study, LVEF and NYHA functional class
are predictive factors of hospitalisation. In line with
this observation, LVEF has been classified as an inde-
pendent factor for heart failure worse prognosis in
the general population and in CRT-D recipients
(26). Indeed, LVEF improvement is an index to
define CRT-D-positive response, and NYHA func-
tional class is an indicator of clinical status and out-
comes (28). Hence, NYHA class worsening is linked
to increasing fatigue, dyspnoea and other symptoms
of failing heart, and may be regulated in positive
manner by pharmacological and electrical therapy in
responders (26).
A clinically relevant result emerging from our
data analysis is that TM is predictive of heart fail-
ure hospitalisation rate. CRT-D recipients are hospi-
talised for dyspnoea worsening, for an increasing
weight and for all symptoms related to heart failure
disease worsening. TM may represent a useful mon-
itoring system to follow heart failure CRT-D recipi-
ents, who may receive an appropriate, safe to use
for physicians and patients (8), continuous follow-
up monitoring and consequently the care that they
need.
The main limitation of this study is the small
size of our population of patients treated by CRT-
D, monitored or not by TM, also attributable to
loss of patients during follow-up, and to the low
adherence of patients to the study protocol, as
mentioned in the results section. Unfortunately, we
do not have sufficient data on sympathetic nervous
activity, which plays a crucial role in the patho-
physiology of heart failure (29–34) and can be
modulated by CRT (35). Besides, our conclusions
remain linked to the relatively short follow-up
duration and should not be extrapolated to long-
term clinical outcomes.
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